ARCHIVES

ODAC Recommends Femara Campath For FDA Approval.

This article is from The Cancer Letter archive.

Vol. 27 No. 01 | January 5, 2001

Download PDF Visit The Full Archive

Related Articles

Varmus: Plan Would Give Trials A Strong Scientific Base

December 17, 2010

In Brief: Adjuvant Chemotherapy Standard Practice For Breast Cancer At Milan, Bonadonna Says

May 7, 1976

Shubik Subcommittee Criticizes New Study Section, Asks NCI To Hire More Epidemiologists

December 5, 1975

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Fisher Seeks Damages Under Privacy Act; NIH Consents To Remove Database Flags

March 10, 1995

Institute of Medicine Elects 80 New Members

October 24, 2014